June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
An In Vitro Reconstructed Normal Human Corneal Tissue Model for Corneal Drug Delivery Studies of Ophthalmic Formulation
Author Affiliations & Notes
  • Yulia Kaluzhny
    MatTek Corporation, Ashland, MA
  • Miriam Kinuthia
    MatTek Corporation, Ashland, MA
  • Viktor Karetsky
    MatTek Corporation, Ashland, MA
  • Laurence d’Argembeau-Thornton
    MatTek Corporation, Ashland, MA
  • Patrick Hayden
    MatTek Corporation, Ashland, MA
  • Mitchell Klausner
    MatTek Corporation, Ashland, MA
  • Footnotes
    Commercial Relationships Yulia Kaluzhny, MatTek Corporation (E); Miriam Kinuthia, MatTek Corporation (E); Viktor Karetsky, MatTek Corporation (E); Laurence d’Argembeau-Thornton, MatTek Corporation (E); Patrick Hayden, MatTek Corporation (E); Mitchell Klausner, MatTek Corporation (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4150. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yulia Kaluzhny, Miriam Kinuthia, Viktor Karetsky, Laurence d’Argembeau-Thornton, Patrick Hayden, Mitchell Klausner; An In Vitro Reconstructed Normal Human Corneal Tissue Model for Corneal Drug Delivery Studies of Ophthalmic Formulation. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4150.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Permeation of topically applied ocular drugs occurs predominantly through the cornea and therefore absorption studies using corneal tissues play a critical role in ocular drug formulation. Currently, most ocular absorption studies use in vivo or ex vivo animal tissues that have many disadvantages including poor standardization, species extrapolation, high cost, and ethical concerns.

Methods: A reconstructed corneal tissue model (EpiCornealTM) was recently developed. The model consists of normal human corneal epithelial cells that have been cultured using serum free medium to form a highly differentiated organotypic corneal epithelial tissue. The multilayered cultures contain tight junctions and develop barrier properties comparable to the in vivo human cornea. Real time qPCR confirmed that the reconstructed tissues express ALDH-A1 and TXNRD1 (corneal epithelium specific enzymes that confer resistance to UV light damage), MUC4 (corneal glycoprotein mucin), and ABCC1 and ABCB1 (efflux transporters with important roles in corneal drug distribution). The permeability of the model was evaluated using compounds with a wide range of properties: a) the hydrophilic dyes sodium fluorescein (NaFl), fluorescein isothiocyanate-labeled dextran (FD-4, MW=4000), and lucifer yellow (LY); b) the hydrophobic dye rhodamine B (RdB), and c) ophthalmic related antibiotics, ofloxacin (OFL) and voriconazole (VCZ). The effect of permeation enhancing agents, 0.01% Benzalkonium Chloride (BAK), 0.05-0.5% EDTA, 0.005% Cetylpyridinium chloride (CPC), and 0.02% Polyoxyethelen-20 stearyl ether (PSE), was investigated.

Results: The permeation coefficient (Kp) for NaFl/ FD-4/ LY/ RdB/ OFL/ and VCZ was 6.0±0.1x10-7/ 5.7±3.8x10-8/ 6.8±0.7x10-7/ 3.5±0.4x10-5/ 1.0±0.2x10-6/ and 3.9±1.1x10-5 cm/s. The Kp’s agree with literature values. 0.25% EDTA increased permeability of NaFl/ FD-4/ LY/ and VCZ by 2.2/ 3.9/ 7.1/ and 4.0 fold, respectively. 0.01% BAC increased the permeability of OFL and VCZ by 3.4 and 18.5 fold, respectively. 0.02% PSE increased the permeability of NaFl and FD-4 by 4.1 and 3.0 fold, respectively.

Conclusions: The reconstructed in vitro EpiCorneal tissue morphology, barrier properties, and permeability resemble those of the in vivo human cornea. This model is anticipated to be a useful tool to evaluate new corneal drug formulations.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×